United Health Products, Inc.
United Health Products, Inc. develops and markets patented hemostatic gauze products for wound care and surgical bleeding control. The company is based in the United States and operates through its CelluSTAT product line and related branded formats, with manufacturing and packaging performed through contract and service providers.
Fiscal year 2025 · change from previous year
Development 2018–2025
Business
Share of revenueCotton-based gauze designed to absorb drainage and help control bleeding.
Superficial wound and external bleeding products used in healthcare settings.
Product formats and trademarks associated with the company’s gauze platform.
Customers
The company’s target customers are healthcare providers that need products for bleeding control and wound management, especially hospitals, surgery centers, clinics, and physicians. Its stated commercial focus also includes the broader human surgical market, where Class III-approved hemostatic agents are used in more demanding procedures.
Buy hemostatic gauze for internal surgical bleeding control and procedural use.
Use the products for superficial wounds, drainage absorption, and external bleeding.
May commercialize, distribute, or acquire the product platform.
Potential channel partners or strategic buyers for the product line.
Strategy
The company is focused on obtaining FDA pre-market approval for its CelluSTAT hemostatic gauze so it can address higher-value surgical markets. It is also evaluating commercialization partnerships, a sale, or a merger with an industry participant rather than building a large independent sales organization.
Regulatory approval is the key gate to the company’s intended surgical market expansion.
A partner can provide distribution, market access, and execution capacity.
Management has indicated a sale or merger may be the preferred long-term path.
Geography
The company is based in the United States, where its products are cut, packaged, and sterilized by service providers. Its stated commercial opportunity includes both domestic and international Class III human surgical markets, although the disclosed operating footprint in the excerpts is primarily U.S.-based.
Risks
The company faces substantial regulatory risk because its core growth plan depends on FDA PMA approval, which cannot be assured. It also has going-concern and financing risk, since it has not yet generated operating revenue and depends on external funding to support development and regulatory work.
The company’s surgical market strategy depends on approval for Class III use.
Exposure: CelluSTAT and the Class III surgical market
The company has not yet reached operating scale sufficient to fund overhead internally.
Exposure: Corporate funding and development operations
Future capital raises may be needed to fund regulatory and commercialization efforts.
Exposure: Common stock issuance and convertible financing
The company does not intend to fully commercialize independently.
Established competitors may have stronger regulatory, sales, and hospital relationships.
Exposure: Wound care and surgical hemostats
Accounting
Judgemental itemsAwards to employees and directors are expensed over the vesting period and can be material relative to revenue.
Impact: Operating expenses and equity dilution
Management and auditors must assess whether financing is sufficient to continue operations.
Impact: Disclosure risk and financial statement presentation
Equity-linked funding arrangements and related-party loans may require judgment in measurement and disclosure.
Impact: Liabilities, equity, and financing costs
Similar listed companies
Publicly listed companies with a comparable business focus.
Celularity Inc
CELU · Pharmaceutical Preparations
UnitedHealth Group Incorporated
UNH · Hospital & Medical Service Plans
UnitedHealth Group is a U.S.-based health care and well-being company organized around two businesses: UnitedHealthcare, which provides health benefits…
Universal Health Services, Inc
UHS · Services-General Medical & Surgical Hospitals, NEC
Universal Health Services is a U.S.-based operator of acute care hospitals, freestanding emergency departments, outpatient centers, and behavioral health facilities.
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Sanara MedTech Inc.
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Humacyte, Inc.
HUMA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026